Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 417

1.

Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.

Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G.

J Urol. 2009 Oct;182(4):1548-54. doi: 10.1016/j.juro.2009.06.058. Epub 2009 Aug 15. Erratum in: J Urol. 2009 Dec;182(6):2985. Dosage error in article text.

PMID:
19683731
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

Kennelly MJ, Lemack GE, Foote JE, Trop CS.

Urology. 2009 Oct;74(4):741-5. doi: 10.1016/j.urology.2009.05.008. Epub 2009 Jul 22.

PMID:
19628264
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.

Franco I, Horowitz M, Grady R, Adams RC, de Jong TP, Lindert K, Albrecht D.

J Urol. 2005 Jan;173(1):221-5.

PMID:
15592080
[PubMed - indexed for MEDLINE]
4.

Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.

Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J.

J Urol. 2007 Jan;177(1):208-13; discussion 213.

PMID:
17162046
[PubMed - indexed for MEDLINE]
5.

Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.

Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ; Propiverine Investigator Group.

Eur Urol. 2007 Jan;51(1):235-42. Epub 2006 May 2.

PMID:
16698176
[PubMed - indexed for MEDLINE]
6.

Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.

Madersbacher H, Mürtz G, Alloussi S, Domurath B, Henne T, Körner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G.

BJU Int. 2009 Mar;103(6):776-81. doi: 10.1111/j.1464-410X.2008.08093.x. Epub 2008 Oct 24.

PMID:
19007380
[PubMed - indexed for MEDLINE]
7.

Oxybutynin topical and transdermal formulations: an update.

Staskin DR, Salvatore S.

Drugs Today (Barc). 2010 Jun;46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750. Review.

PMID:
20571610
[PubMed - indexed for MEDLINE]
8.

Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.

Lazzeri M, Calò G, Spinelli M, Malaguti S, Guerrini R, Salvadori S, Beneforti P, Regoli D, Turini D.

J Urol. 2006 Nov;176(5):2098-102.

PMID:
17070267
[PubMed - indexed for MEDLINE]
9.

Intravesical oxybutynin in the pediatric neurogenic bladder.

Lazarus J.

Nat Rev Urol. 2009 Dec;6(12):671-4. doi: 10.1038/nrurol.2009.214. Epub 2009 Nov 10. Review.

PMID:
19901914
[PubMed - indexed for MEDLINE]
10.

Transdermal oxybutynin.

Baldwin CM, Keating GM.

Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. Review.

PMID:
19275276
[PubMed - indexed for MEDLINE]
11.

Transdermal drug delivery treatment for overactive bladder.

Dmochowski RR, Starkman JS, Davila GW.

Int Braz J Urol. 2006 Sep-Oct;32(5):513-20. Review.

PMID:
17081319
[PubMed - indexed for MEDLINE]
Free Article
12.

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.

J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.

PMID:
19233423
[PubMed - indexed for MEDLINE]
13.
14.

Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience.

Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I.

Int J Urol. 2004 Aug;11(8):592-6.

PMID:
15285747
[PubMed - indexed for MEDLINE]
15.

Transdermal oxybutynin: for overactive bladder.

Bang LM, Easthope SE, Perry CM.

Drugs Aging. 2003;20(11):857-64.

PMID:
12964892
[PubMed - indexed for MEDLINE]
16.

Transdermal oxybutynin for overactive bladder.

Davila GW, Starkman JS, Dmochowski RR.

Urol Clin North Am. 2006 Nov;33(4):455-63, viii.

PMID:
17011381
[PubMed - indexed for MEDLINE]
17.

Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.

Grigoleit U, Mürtz G, Laschke S, Schuldt M, Goepel M, Kramer G, Stöhrer M.

Eur Urol. 2006 Jun;49(6):1114-20; discussion 1120-1. Epub 2006 Mar 3.

PMID:
16542772
[PubMed - indexed for MEDLINE]
18.

Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review.

Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M.

J Urol. 2008 Sep;180(3):1091-7. doi: 10.1016/j.juro.2008.05.056. Epub 2008 Jul 18. Review.

PMID:
18639290
[PubMed - indexed for MEDLINE]
19.

The evolution of transdermal therapy for overactive bladder.

Sand PK.

Curr Urol Rep. 2009 Sep;10(5):338-41.

PMID:
19709479
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.

Lehtoranta K, Tainio H, Lukkari-Lax E, Hakonen T, Tammela TL.

Scand J Urol Nephrol. 2002 Feb;36(1):18-24.

PMID:
12002352
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk